Table 1.
Patient characteristics.
| Characteristic | Total (n = 215) |
|---|---|
| Age, median (SD) | 78 (4.9) |
| Sex | |
| Male | 125 (58%) |
| Female | 90 (32%) |
| Metastatic status | |
| M0 | 110 (51%) |
| M1 | 105 (49%) |
| Chemotherapy | |
| Standard therapy | 100 (47%) |
| Reduced therapy or monotherapy | 115 (53%) |
| Capecitabine | 77 (36%) |
| Capecitabine-Oxaliplatin | 33 (15%) |
| Oxaliplatin-5FU-anti-EGFR | 32 (15%) |
| Oxalipatin-5FU-Bevacizumab | 40 (18%) |
| Oxaliplatin-Irinotecan-5FU | 15 (7%) |
| Irinotecan-anti-EGFR | 6 (3%) |
| Capecitabine-Bevacizumab | 12 (6%) |
| MAX2 index | |
| 0 | 73 (34%) |
| 1 | 127 (59%) |
| 2 | 15 (7%) |
| ECOG PS | |
| 0 | 58 (27%) |
| 1 | 144 (67%) |
| 2 | 13 (6%) |
| IADL | |
| 8 | 97 (45%) |
| ≤7 | 118 (55%) |
| ADL | |
| 6 | 181 (84%) |
| ≤5 | 34 (16%) |
| Number of falls in the past 6 months | |
| None | 183 (85%) |
| ≥1 | 32 (15%) |
| SPPB | |
| >7 | 185 (86%) |
| ≤6 | 30 (14%) |
| Charlson comorbidity score | |
| 0 | 80 (37%) |
| 1 | 64 (30%) |
| ≥2 | 71 (33%) |
| Pfeiffer test | |
| 0–2 errors | 185 (86%) |
| ≥3 errors | 30 (14%) |
| Unintentional weight loss % | |
| ≤10% | 181 (88%) |
| >10% | 34 (12%) |
| VES 13 | |
| 0–2 | 103 (48%) |
| ≥3 | 119 (52%) |
| Toxicity | |
| G3-5 | 73 (34%) |
| G0-2 | 142 (66%) |
| Early death < 6 months | |
| Yes | 47 (22%) |
| No | 168 (78%) |
| Unplanned hospitalizations | |
| Yes | 60 (28%) |
| No | 155 (67%) |
Abbreviations: SD: Standard deviation, 5FU: 5-Fluorouracil, EGFR: Epidermal Growth Factor Receptor, ADL: Activity of Daily Living, IADL: Instrumental activity of Daily Living, ECOG PS: Eastern Cooperative Oncology Group performance status. SPPB, Short Physical Performance Battery, VES-13: Vulnerable Elders Survey-13.